Targeting EWS-FLI1: A Midsummer Night's Dream to Improve Survival for Patients with Ewing Sarcoma (and Other Tales of the Bard)

Pathology Grand Rounds

Thursday May 24, 2018 at 12:00 PM


This grand round has already taken place.


Pathology Classroom - Stony Brook, NY
May 24th, 2018
1.00 AMA PRA Category 1 Credit Hours

Description

In 2009, Dr. Toretsky and his team revealed the molecule called YK-4-279 that targets Ewing Sarcoma with an article in Nature Medicine. YK-4-279 has the potential to be a potent new strategy in the fight against not only Ewing Sarcoma, but also other cancers and diseases with similar characteristics. YK-4-279 is an inhibitor of EWS-FLI1 oncoprotein. Dissection of EWS-FLI1 function with YK-4-279 has revealed activity in splicing and possibly chromatin regulation.

Dates and Times

Start: 5/24/2018 12:00 PM
End: 5/24/2018 1:00 PM

Objectives

1. Recognize EWS-FLI1 as a therapeutic target in Ewing Sarcoma
2. Understand the challenge of creating a drug to inhibit EWS-FLI1
3. Recognize EWS-FLI1 regulates mRNA splicing

Speakers

  • Dr. Jeffrey Alan Toretsky
    • Targeting EWS-FLI1: A Midsummer Night's Dream to Improve Survival for Patients with Ewing Sarcoma (and Other Tales of the Bard)

Location

Pathology Classroom
Basic Science Tower
Level 9 Room 145
Stony Brook, NY 11950

Accreditation

The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) . Physicians should only claim the credit commensurate with the extent of their participation in the activity.